TLSI
TriSalus Life Sciences, Inc.
NASDAQ · USHealthcareMedical - Devices
$4.31+0.47%
Price as of Jul 20, 2026
TLSI growth
TriSalus Life Sciences, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +39.6%
- EBITDA
- +5.5%
- EBIT
- +11.9%
- EPS
- -24.8%
- Free cash flow
- +42.8%
- Operating cash flow
- +42.0%
Forward estimates
- Revenue
- +85.6%
- EBITDA
- —
- EPS
- +94.6%
Three-year CAGR
- Revenue
- +53.9%
- EBITDA
- -2.1%
- EBIT
- +25.5%
- Net income
- -18.0%
- EPS
- -47.2%
- Free cash flow
- +54.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.